H.C. Wainwright analyst Arthur He CFA has maintained their bullish stance on SLDB stock, giving a Buy rating on March 20.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arthur He CFA has given his Buy rating due to a combination of factors, most notably the compelling clinical profile of lead asset SGT-003 in Duchenne muscular dystrophy. Interim Phase 1/2 data showed strong and consistent micro-dystrophin expression across multiple assays, along with encouraging signals on muscle integrity and cardiac function, while maintaining a generally clean safety profile and positioning the program for a potential accelerated approval discussion with the FDA in 2026.
In addition, He highlights the emerging pipeline value from SGT-212 in Friedreich’s ataxia and SGT-501 in CPVT, with both programs advancing into early-stage clinical trials and initial data expected in 2H26. He also points to the company’s strengthened balance sheet, with pro forma cash of about $414M expected to support operations into the first half of 2028, providing Solid Biosciences with sufficient runway to reach several key clinical and regulatory catalysts that can drive shareholder value.
In another report released on March 20, Needham also assigned a Buy rating to the stock with a $19.00 price target.